Pakistan sets aside $100m to buy Covid vaccine

ISLAMABAD: SLAMABAD: While an estimated cost of the h Covid-19 d vaccine is not yet available, l bl Prime Minister Imran Khan has approved a $100 million allocation and allowed advance payment for procurement of the vaccine at the th earliest.

Moreover, it has been decided that different segments of society, such as senior citizens, health practitioners and people suffering from chronic diseases, will be prioritised for th the vaccine that will be available in limited n numbers during the ongoing winter season. “A “As we speak no company has announced th the cost of vaccine. Moreover, not a sing gle company has got the approval to sell th the vaccine as the clinical trial data is limit ited. Although international firms — Pfizer a and BioNTech — have announced that the phase-III clinical trials of their vaccines had shown 90 per cent efficacy in preventing the disease among those who have not contracted the virus, but they are in the process of

compiling the data. Once data will be completed they will submit it with United States Food and Drugs Authority and with similar regulatory authority of the European Union. It may take another four weeks,” said Vice Chancellor of the Health Services Academy (HSA) and Chairman of the National Vaccine Committee Dr Asad Hafeez while talking to Dawn. “Companies will get the emergency use or transit permission for use of vaccine and after one year they may get full approval to sell the vaccine. However, there will be no difference for the general public if the vaccine is sold under transit or full permission. The Ministry of National Health Services (NHS) has been interacting and negotiating with half a dozen multinational companies to get the vaccine at the earliest,” he said. In reply to a question, Dr Hafeez said the government was very close to finalise the process for the procurement of the vaccine. However, he said, it would take a few more months to get the vaccine. An official of the health ministry requesting anonymity said that it was not possible to estimate the cost of the vaccine at the moment, as there were no mRNA (messenger RNA) vaccines in the world. “We should [also] not forget that commercial companies are manufacturing the vaccine and, despite their announcement that the vaccine will be provided at affordable rates, we should not expect that it will be available for almost free,” he said.